Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis

Conclusions: The aggregate response benefit in skin clearance and itch reduction favored upadacitinib 30 mg over dupilumab and upadacitinib 15 or 30 mg over placebo. These benefits may translate to overall greater improvements in patient QoL.PMID:38108653 | DOI:10.1089/derm.2023.0153

Source: Dermatitis - December 18, 2023 Category: Dermatology Authors: Jonathan I Silverberg Marjolein de Bruin-Weller Brian M Calimlim Xiaofei Hu Sarah A Ofori Andrew M Platt Henrique D Teixeira Kilian Eyerich Jacob P Thyssen Source Type: research